8-K: MAIA Biotech Secures $2.3M NIH Grant for Lung Cancer Trial

MAIA Biotechnology received a $2.3 million grant from the National Institutes of Health to expand its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer.

Summary

• MAIA Biotechnology, Inc. was awarded a $2.3 million grant by the National Institutes of Health (NIH).
• The grant will support the expansion of the THIO-101 Phase 2 clinical trial evaluating ateganosine.
• Ateganosine is being developed as a third-line treatment for patients with advanced non-small cell lung cancer (NSCLC).
• The funds are specifically intended to support expenses related to the enrollment of U.S. patients who are resistant to chemo and immunotherapy.
• NIH grant allocations will be distributed over three years, from 2025 to 2027.
• In Parts A and B of THIO-101, median overall survival (OS) for 22 patients in third-line treatment was 17.8 months as of June 30, 2025, with a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months.
• Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown overall survival of 5 to 6 months.
• The first patient in the expansion phase of the trial was dosed in July 2025 in Taiwan.
• FDA Investigational New Drug (IND) clearance for THIO-101 was received in 2023, enabling immediate enrollment of U.S. patients.

Sentiment

Score: 9

Explanation: The filing announces a significant non-dilutive grant, positive clinical trial data showing superior efficacy compared to standard of care, and expansion of a key clinical trial into the U.S. market, all of which are strong positive indicators for the company's progress and future prospects.

Positives

• Secured a $2.3 million non-dilutive grant from the National Institutes of Health, providing significant funding for clinical development.
• The grant enables the expansion of the THIO-101 Phase 2 trial into the U.S., broadening the patient pool and accelerating development.
• Ateganosine demonstrated a median overall survival of 17.8 months in Parts A and B of the trial, significantly exceeding the 5-6 months observed with standard-of-care chemotherapy in similar settings.
• The trial addresses a significant unmet clinical need in third-line NSCLC, where no established standard of care currently exists.
• FDA Investigational New Drug (IND) clearance for THIO-101 in 2023 allows for immediate enrollment of U.S. patients.
• Ateganosine has shown an acceptable safety profile to date in a heavily pre-treated patient population.

Risks

• The initiation, timing, cost, progress, and results of preclinical and clinical studies and research and development programs may differ from expectations.
• Ability to advance product candidates into, and successfully complete, clinical studies is uncertain.
• Timing or likelihood of regulatory filings and approvals is not guaranteed.
• Ability to develop, manufacture, and commercialize product candidates and improve manufacturing processes may face challenges.
• The rate and degree of market acceptance of product candidates are uncertain.
• The size and growth potential of the markets for product candidates and the ability to serve those markets may not meet expectations.
• Ability to obtain and maintain intellectual property protection for product candidates is not assured.

Future Outlook

The company expects to enroll U.S. patients in the expansion phase of the THIO-101 trial immediately, leveraging the FDA IND clearance from 2023 and the newly awarded NIH grant. The grant funds will be distributed over three years (2025-2027) to support this expansion, aiming to further validate ateganosine's efficacy and address the unmet need in third-line NSCLC.

Management Comments

• "We are thrilled to receive this prestigious NIH grant for the expansion of our Phase 2 trial. It's a great honor to have the support of the National Institutes of Health as we seek to further validate the efficacy of our lead agent ateganosine and its potential to be a breakthrough treatment within the vastly underserved NSCLC market." Vlad Vitoc, M.D., CEO.
• "The NIH grant is a tremendous achievement and a testament to the dedication, collaboration, and hard work of everyone involved in the clinical development of ateganosine." Victor Zaporojan, M.D., MAIA's Senior Medical Director.
• "Ateganosine represents a potential solution for the significant unmet clinical need in third-line NSCLC, where no established standard of care exists and where the overall survival outcomes observed with ateganosine have not been achieved by other therapies." Victor Zaporojan, M.D., MAIA's Senior Medical Director.
• "By enrolling patients in the United States, our trial will gain access to a substantially larger patient pool across multiple continents, further strengthening the impact and relevance of our study." Victor Zaporojan, M.D., MAIA's Senior Medical Director.

Industry Context

The biopharmaceutical industry, particularly in oncology, heavily relies on successful clinical trial outcomes and non-dilutive funding. This NIH grant positions MAIA Biotechnology favorably by providing significant financial support and external validation for its lead candidate, ateganosine, in a challenging indication like third-line advanced NSCLC, where current standard-of-care options offer limited survival benefits. The expansion into the U.S. patient pool is crucial for accelerating trial progress and increasing the robustness of the study data, aligning with broader industry trends of seeking diverse patient populations for clinical development.

Comparison to Industry Standards

• Ateganosine's median overall survival (OS) of 17.8 months in third-line advanced NSCLC significantly surpasses the 5 to 6 months OS typically observed with standard-of-care chemotherapy treatments in similar settings.
• The company highlights that no established standard of care exists for third-line NSCLC, positioning ateganosine as a potential breakthrough in an underserved market.
• The NIH grant provides strong external validation of the scientific merit and potential of ateganosine, comparable to how other leading oncology programs often secure significant government or foundation funding for critical clinical development.

Stakeholder Impact

• Shareholders: Positive impact due to non-dilutive funding, validation of the lead asset, and potential for accelerated clinical development and market access, which could increase company valuation.
• Patients: Potential for a new, more effective third-line treatment option for advanced non-small cell lung cancer, especially for those resistant to current therapies, offering improved survival outcomes.
• Employees: Positive impact on morale and job security due to successful grant acquisition and clinical progress, potentially leading to further growth and opportunities.
• Regulatory Authorities (FDA): Continued engagement through IND clearance and ongoing clinical trials, with potential for future regulatory filings based on trial success.
• National Institutes of Health (NIH): Successful allocation of research funds towards a promising cancer therapy, aligning with their mission to improve public health.

Next Steps

• Enroll U.S. patients in the expansion phase of the THIO-101 Phase 2 clinical trial immediately.
• Continue the distribution of the $2.3 million NIH grant allocations over three years (2025-2027).
• Further validate the efficacy of ateganosine in the expanded trial.
• Assess overall response rates (ORR) in advanced NSCLC patients receiving third-line therapy who were resistant to previous checkpoint inhibitor treatments and chemotherapy.

Key Dates

Recommendation

The company secured a significant non-dilutive grant from the NIH, validating its lead asset, ateganosine. The reported median overall survival of 17.8 months in a challenging third-line NSCLC setting is substantially better than the 5-6 months for standard-of-care chemotherapy, indicating strong clinical potential. The expansion of the Phase 2 trial into the U.S. will broaden the patient pool and accelerate development, addressing a significant unmet medical need. These factors collectively present a highly positive outlook for the company's future and its stock.

Keywords

MAIA Biotechnology, THIO-101, Ateganosine, NSCLC, Lung Cancer, Clinical Trial, Phase 2, NIH Grant, Immunotherapy, Oncology, Biopharmaceutical